On April 29, 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, reported that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s (ASCO) (Free ASCO Whitepaper) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 – 8 June (Press release, Immutep, APR 29, 2021, View Source [SID1234578869]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstracts will be available from 5pm US Eastern Time on 19 May 2021. Poster presentations with new and updated data that are not part of the abstract will be released on ASCO (Free ASCO Whitepaper).org at the times indicated below and will subsequently be made available on Immutep’s website at www.immutep.com.
In addition, Immutep plans to hold a webcast after ASCO (Free ASCO Whitepaper) to discuss the data and results, as well as to provide an update on the Company’s business.
TACTI-002 Posters
Title: Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.
Session Title: Poster Session: Lung Cancer – Non-Small Cell Metastatic
Date: On demand session available from 9am on 4 June 2021 US Eastern Time
Presenter: Dr Tim Clay, Investigator, St John of God Subiaco Hospital, Perth, Australia
Abstract: 9046
Title: Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.
Session Title: Poster Session: Head and Neck Cancer
Date: On demand session available from 9am on 4 June 2021 US Eastern Time
Presenter: Dr Irene Brana, Investigator, Vall d’Hebron Institute of Oncology, Barcelona, Spain
Abstract: 6028
INSIGHT-004 Poster
Title: Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.
Session Title: Poster Discussion Session, Developmental Therapeutics – Immunotherapy
Date: On demand session available from 9am on 4 June 2021 US Eastern Time
Presenter: Thorsten Oliver Goetze, MD; Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt am Main, Germany
Abstract: 2518
Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000
ABN: 90 009 237 889
About American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Conference
ASCO’s annual meeting represents the world’s largest gathering of oncology physicians, industry representatives, researchers, patient advocates, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology, and to gain insights for improving cancer care. For additional information on the 2021 ASCO (Free ASCO Whitepaper)’s Annual meeting, please visit View Source
About TACTI-002
TACTI-002 (Two ACTive Immunotherapies) is a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as "MSD" outside the United States and Canada). The study is evaluating the combination of efti with MSD’s KEYTRUDA (pembrolizumab) in up to 183 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.
About INSIGHT-004 (also known as INSIGHT Stratum D)
INSIGHT-004 is a Phase I clinical trial and is the fourth arm of the investigator-initiated INSIGHT trial which is being conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt. It is being conducted under Immutep’s collaboration with Merck KGaA and Pfizer Inc., and is evaluating the safety, tolerability and recommended Phase II dose of efti when given in combination with avelumab, a human anti-PD-L1 antibody, in 12 patients with solid cancers. Avelumab is co-developed and co-commercialised by Merck KGaA, Darmstadt, Germany and Pfizer Inc.